Jiuzhitang Maker signs a "Joint Construction Agreement for a Stem Cell Clinical Research Base" with Beijing Tiantan Hospital.
2018-09-14
In September 2018, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. signed a "Joint Construction Agreement for a Stem Cell Clinical Research Base" with Beijing Tiantan Hospital, Affiliated to Capital Medical University. The two parties agreed to prioritize collaborative stem cell clinical research focused on disease indications where stem cell therapy shows significant potential. Additionally, experts from Tiantan Hospital will serve as the principal investigators for Meike New Drug’s applications seeking regulatory approval of "stem cell therapy for post-stroke sequelae" and "stem cell therapy for Alzheimer's disease." Together, they will jointly conduct clinical trials for these innovative treatments. Looking ahead, the partners plan to expand their research into the therapeutic efficacy of stem cell-based drugs, further exploring the potential of stem cells in addressing additional medical conditions.

Previous:
Related News